Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adjuvanted recombinant 2009 h1n1 pandemic influenza vaccine
- Development stage
- Unknown
- Lead developer
- Vaxine
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The adjuvanted recombinant 2009 H1N1 pandemic influenza vaccine is a protein subunit vaccine developed by Vaxine Pty Ltd. It consists of a recombinant hemagglutinin (rHA) protein derived from the A/California/04/2009 (H1N1) pandemic strain, produced using a baculovirus expression system in insect cells. The vaccine is formulated with Advax, a proprietary adjuvant based on delta-inulin particles that enhances both humoral and cellular immune responses. Clinical trials, such as NCT01014806, evaluated the vaccine's safety and immunogenicity in healthy adults, demonstrating its ability to induce high titers of neutralizing antibodies with a favorable safety profile. This candidate was part of the rapid response efforts during the 2009 H1N1 influenza pandemic.
- Other names
- Recombinant H1N1 vaccine with Advax adjuvantrHA H1N1 vaccine
02
Targets
B-cell receptor specific for hemagglutinin epitopes from A/California/07/2009 (H1N1)pdm09Hemagglutinin-specific CD4+ T-cell receptor (HA-specific TCR)Influenza Hemagglutinin-specific CD8+ T-cell receptor
Beyond the preview
Go deeper on adjuvanted recombinant 2009 h1n1 pandemic influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adjuvanted recombinant 2009 h1n1 pandemic influenza vaccine.